Osaka, Japan

Shingo Mizushima

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 5.8

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2017-2023

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Shingo Mizushima: Innovator in Medicinal Chemistry

Introduction

Shingo Mizushima is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that have therapeutic applications. With a total of 5 patents to his name, Mizushima's work focuses on innovative solutions for bacterial infections and other diseases.

Latest Patents

Mizushima's latest patents include an oxo-substituted compound that exhibits an excellent β-lactamase inhibitory effect. This novel compound, represented by specific formulas, can be used either alone or in combination with β-lactam drugs to create effective preventive or therapeutic agents for bacterial infections. Additionally, he has developed a method for producing a benzimidazole derivative, which serves as a medicament and an intermediate for preparing other medicinal compounds.

Career Highlights

Throughout his career, Mizushima has worked with notable organizations such as Sumitomo Dainippon Pharma Co., Ltd. and The Kitasato Institute. His experience in these companies has allowed him to refine his expertise in drug development and medicinal chemistry.

Collaborations

Mizushima has collaborated with esteemed colleagues, including Toshio Kanai and Masafumi Komiya. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Shingo Mizushima's innovative work in medicinal chemistry has led to the creation of valuable compounds that address critical health challenges. His contributions continue to impact the field positively, showcasing the importance of research and development in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…